Charts

Investors considering a purchase of Voyager Therapeutics Inc (VYGR) shares, but cautious about paying the going market price of $7.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $5 strike, which has a bid at the time of this writing of 30 cents..

Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously a

NorthStar Appoints Peter Pfreundschuh to Board of Managers

Voyager Therapeutics (NASDAQ:VYGR) has had a rough week with its share price down 14%. However, a closer look at its...

Looking back to 95 days ago, Voyager Therapeutics Inc (VYGR) priced a 7,777,778 share secondary stock offering at $9.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Voyager Therapeutics has surely tried investors’ patience since it came public eight years ago. The biotech firm’s stock has fallen as low as $2.50 from a peak of $30, as its early programs to treat neurological diseases didn’t pan out. Analysts at Guggenheim Securities initiated coverage of the Lexington, Mass.-based biotech with a Buy rating earlier this week.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree US.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem. As a Reuters report mentioned recently, publicly traded technology enterprises witnessed a huge outflow of $4.4 billion. In fact, it was the largest-ever outflow of funds over a single… The post The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby Ferguson, M.D., Ph.D. that, among other things, provides for the grant to Dr. Ferguson of a non-qualified stock option and restricted stock units as an inducement material to Dr. Ferguson’s entering into employment with Voyager. The inducement awards were approved by the Compensati

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If soaring consumer prices got you down, you may want to consider these value stocks under $20. Sure, the market may be booming during this unique post-pandemic cycle. Still, there’s always an opportunity to be discovered. Basically, it comes down to simple math. I can’t nail down a specific number. But apparently, if you include… The post Cheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

H.C. Wainwrightinitiated coverage onVoyager Therapeutics Inc(NASDAQ:VYGR), noting a growing franchise of novel, ...

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare disea

In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds. If you want to skip our discussion on the biotech industry, head over to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. Fitch Ratings maintains a Neutral outlook for the global pharmaceutical and biotech industry in […]

Today is shaping up negative for Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders, with the analysts delivering...

Q4 2023 Voyager Therapeutics Inc Earnings Call

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript February 28, 2024 Voyager Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.25, expectations were $-0.59. Voyager Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day. Thank you […]

Thursday’s premarket trading session saw substantial upward momentum propelled by major tech stocks, laying the groundwork for a ...

Shares of Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

Pro-Forma Cash of $431 Million Sets Stage for Clinical Advancements into 2027

Gainers IGC Pharma (AMEX:IGC) shares moved upwards by 14.6% to $0.4 during Wednesday's after-market session. The market value of their ...

Voyager Therapeutics (NASDAQ:VYGR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:00 PM. Here's what investors ...

- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially enabling the generation of clinical data from multiple programs - - Lead development candidates selected in Friedreich’s ataxia gene therapy program in collaboration with Neurocrine Biosciences, triggering $5 mill

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue ...

Voyager Therapeutics (NASDAQ:VYGR) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet. To mitigate the downside risks, it may be better to consider undervalued enterprises. Of course, specifically targeting biotech stocks that trade… The post 7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program. The candidate combines a frataxin (FXN) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived fro

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results. To participate via telephone and join the call live, please register i

- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to be presented at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024) - LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medi

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $72.51 per unit.

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on February 14, 2024, at 11:20 a.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

Investors considering a purchase of Voyager Therapeutics Inc (VYGR) shares, but cautious about paying the going market price of $7.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $5 strike, which has a bid at the time of this writing of 15 cents..

Key Insights Significant control over Voyager Therapeutics by individual investors implies that the general public has...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The 2024 investment trends are slowly making themselves known. Make sure you follow our guide to stay ahead of the curb. The post Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Looking back to 4 days ago, Voyager Therapeutics Inc (VYGR) priced a 7,777,778 share secondary stock offering at $9.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's ...

Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released ...

In trading on Friday, biotechnology shares were relative laggards, down on the day by about 1.1%. Helping drag down the group were shares of Voyager Therapeutics, down about 18.5% and shares of Allogene Therapeutics off about 16.2% on the day.

Gainers Ainos (NASDAQ:AIMD) shares rose 150.3% to $4.33 during Friday's pre-market session. The company's market cap stands at $20.2 ...

Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. Shares of Franklin Covey ...

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who so choose in lieu of common stock, pre-funded warrants to purchase an aggregate of 3,333,333 shares of common stock at a public offering price of $8.999 per pre-f

Voyager Therapeutics, Inc.(NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a ...

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock increased by 113.1% to $1.3 during Thursday's after-market session. The market value ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Voyager Therapeutics Inc (VYGR), where a total volume of 3,552 contracts has been traded thus far today, a contract volume which is representative of approximately 355,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.1% of VYGR's average daily trading volume over the past month, of 753,690 shares..

Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods ...

Gainers NexImmune (NASDAQ:NEXI) shares moved upwards by 230.5% to $7.85 during Wednesday's regular session. The market value of their ...

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose ...

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow ...

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. The post VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Voyager Therapeutics Inc(NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement withNovartis Pharma ...

Novartis expanded its gene therapy collaboration with Voyager on Monday, and VYGR stock rocketed above its 200-day line.

Gainers Longboard Pharmaceuticals (NASDAQ:LBPH) shares increased by 157.0% to $15.5 during Tuesday's pre-market session. The market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital ecosystem, society will continue to invest in clinical breakthrough stocks in the hopes of forwarding treatments to vexing conditions and diseases. In other words, targeting undervalued.... The post 7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $69.96 per unit.

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

Gainers Bone Biologics (NASDAQ:BBLG) stock increased by 64.3% to $0.89 during Thursday's pre-market session. The market value of their ...

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on ...

Voyager Therapeutics (NASDAQ:VYGR) is set to give its latest quarterly earnings report on Monday, 2023-11-06. Here's what investors need ...

Investors considering a purchase of Voyager Therapeutics Inc (VYGR) stock, but cautious about paying the going market price of $6.66/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2024 put at the $5 strike, which has a bid at the time of this writing of 15 cents..

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue ...